vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and POET TECHNOLOGIES INC. (POET). Click either name above to swap in a different company.
POET TECHNOLOGIES INC. is the larger business by last-quarter revenue ($298.4K vs $169.0K, roughly 1.8× Aligos Therapeutics, Inc.). Over the past eight quarters, POET TECHNOLOGIES INC.'s revenue compounded faster (13.2% CAGR vs -50.7%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
POET Technologies designs and develops photonic integrated circuits based on its proprietary Optical Interposer platform. Headquartered in Toronto with operations in Singapore, the company supplies optical engines and transceivers used in AI data centers, high-speed networking, and sensing applications.
ALGS vs POET — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $298.4K |
| Net Profit | — | $-9.4M |
| Gross Margin | — | — |
| Operating Margin | — | -3201.6% |
| Net Margin | — | -3139.6% |
| Revenue YoY | -72.1% | — |
| Net Profit YoY | 75.8% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | $298.4K | ||
| Q3 25 | $741.0K | $268.5K | ||
| Q2 25 | $965.0K | $166.8K | ||
| Q1 25 | $311.0K | — | ||
| Q4 24 | $606.0K | — | ||
| Q3 24 | $1.3M | $177.4K | ||
| Q2 24 | $1.1M | — | ||
| Q1 24 | $694.0K | — |
| Q4 25 | — | $-9.4M | ||
| Q3 25 | $-31.5M | $-17.3M | ||
| Q2 25 | $-15.9M | $6.3M | ||
| Q1 25 | $43.1M | — | ||
| Q4 24 | $-82.2M | — | ||
| Q3 24 | $-19.3M | $-8.0M | ||
| Q2 24 | $5.1M | — | ||
| Q1 24 | $-34.9M | — |
| Q4 25 | — | -3201.6% | ||
| Q3 25 | -3827.4% | -3261.9% | ||
| Q2 25 | -1924.0% | -5718.6% | ||
| Q1 25 | -6187.5% | — | ||
| Q4 24 | -3393.2% | — | ||
| Q3 24 | -1610.5% | -3809.2% | ||
| Q2 24 | -2489.5% | — | ||
| Q1 24 | -3176.7% | — |
| Q4 25 | — | -3139.6% | ||
| Q3 25 | -4256.0% | -6430.3% | ||
| Q2 25 | -1643.8% | 3802.8% | ||
| Q1 25 | 13854.7% | — | ||
| Q4 24 | -13556.1% | — | ||
| Q3 24 | -1540.7% | -4498.5% | ||
| Q2 24 | 477.0% | — | ||
| Q1 24 | -5023.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | $-3.04 | — | ||
| Q2 25 | $-1.53 | $-0.12 | ||
| Q1 25 | $-2.11 | — | ||
| Q4 24 | $-13.10 | — | ||
| Q3 24 | $-3.07 | — | ||
| Q2 24 | $0.81 | — | ||
| Q1 24 | $-5.58 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | — |
| Total Assets | $88.5M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | — | ||
| Q3 25 | $99.1M | — | ||
| Q2 25 | $122.9M | — | ||
| Q1 25 | $137.9M | — | ||
| Q4 24 | $56.9M | — | ||
| Q3 24 | $74.9M | — | ||
| Q2 24 | $94.5M | — | ||
| Q1 24 | $112.7M | — |
| Q4 25 | $53.5M | — | ||
| Q3 25 | $71.8M | — | ||
| Q2 25 | $101.9M | — | ||
| Q1 25 | $116.4M | — | ||
| Q4 24 | $-29.0M | — | ||
| Q3 24 | $50.1M | — | ||
| Q2 24 | $67.2M | — | ||
| Q1 24 | $59.8M | — |
| Q4 25 | $88.5M | — | ||
| Q3 25 | $109.8M | — | ||
| Q2 25 | $134.7M | — | ||
| Q1 25 | $150.7M | — | ||
| Q4 24 | $70.1M | — | ||
| Q3 24 | $88.4M | — | ||
| Q2 24 | $108.8M | — | ||
| Q1 24 | $127.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-14.6M |
| Free Cash FlowOCF − Capex | — | $-17.5M |
| FCF MarginFCF / Revenue | — | -5851.0% |
| Capex IntensityCapex / Revenue | — | 958.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-46.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | $-14.6M | ||
| Q3 25 | $-24.3M | $-9.1M | ||
| Q2 25 | $-15.5M | $-9.0M | ||
| Q1 25 | $-20.9M | — | ||
| Q4 24 | $-18.4M | — | ||
| Q3 24 | $-20.1M | $-8.4M | ||
| Q2 24 | $-19.5M | — | ||
| Q1 24 | $-22.7M | — |
| Q4 25 | — | $-17.5M | ||
| Q3 25 | — | $-11.0M | ||
| Q2 25 | — | $-9.5M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-8.5M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -5851.0% | ||
| Q3 25 | — | -4101.6% | ||
| Q2 25 | — | -5698.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -4802.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 958.2% | ||
| Q3 25 | — | 712.3% | ||
| Q2 25 | — | 313.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 68.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.42× | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
